Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued a follow-up statement to the memorandum issued by Attorney General Jeff Sessions on January 4, 2018, concerning marijuana enforcement and the repeal of the Cole Memo. In the update, Veritas noted that the AG’s decision largely relates to the recreational cannabis marketplace, in which individual states have allowed sales over the last 24 months. Conversely, the company notes, it does not affect the medical cannabis marketplace. As such, Veritas intends to build on its commitment to advancing the science of medical cannabis in the U.S. states where it is currently legal. Through majority-owned subsidiary Cannevert Therapeutics Ltd., Veritas will continue to support the growing demand for reliable medical grade cannabis aimed at treating a range of conditions, including pain, nausea, epilepsy and PTSD. The company will also continue to actively engage with advisors at both the state and federal levels to provide assistance to government officials regarding the policymaking initiatives currently shaping the medical cannabis market across the United States.
To view the full press release, visit http://dtn.fm/D1sq7
Let us hear your thoughts: Veritas Pharma Inc. Message Board
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through its 80% owned Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. For more information, visit the company’s website at www.veritaspharmainc.com
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.